Express Mail Label No. EV 274269204 US



(D)

PATENT
Docket No. H 3763 PCT/US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kropf et al. Art Unit: 1614

Appl. No.: 09/868,379 Examiner: Michelle Graffeo

Filed: August 15, 2001 Customer No.: 00423

Confirm. No.: 8884

Title: FINE SUSPENSIONS OF POORLY SOLUBLE CALCIUM

SALTS AND THEIR USE IN DENTAL CARE PRODUCTS

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Under 37 C.F.R. §§ 1.56 and 1.97(b) Applicants disclose to the Examiner the documents listed on the attached IDC form PTO-1449. Applicants have omitted copies of each cited U.S. reference as waived under 37 C.F.R. § 1.98(a)(2)(i); a copy of each other cited document is enclosed. For the non-English documents, Applicants have cited to an English-language equivalent or provided a translation of the document into English. Applicants respectfully ask the Examiner to consider each document and note that consideration where provided on the IDC.

This Statement does not represent that a search was made or that no better art exists and does not constitute an admission that the listed documents are material or constitute prior art. Therefore Applicants reserve the

PATENT Docket No. H 3763 PCT/US

right to present to the Examiner the relevant facts and law regarding the status of each listed document. Applicants further reserve the right to take appropriate action to establish patentability of the claimed invention over the listed documents, should any be applied against the claims.

This Statement is being filed along with the RCE, and therefore fee for submitting this Supplemental no Information Disclosure Statement is due. However, the Commissioner is hereby authorized to charge Deposit Account No. 01-1250 if any fee under 37 C.F.R. § 1.17(p) is needed have this statement entered and the references to considered by the Patent and Trademark Office.

Respectfully submitted,

Glenn E. J. Murpk (Reg. No.33,539)

Attorney for Applicants

610-278-4926

GEM/img

Henkel Corporation Law Department 2200 Renaissance Boulevard, Suite 200 Gulph Mills, PA 19406

## Enclosures

1. PTO-1449 w/references

PTO/SB/08A (10-01)

09/868,379

August 15, 2001

Approved for use through 10/31/2004. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

Dider the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB Control number

Substitute for form 1449A/PTO

## **SUPPLEMENTAL** INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**First Named Inventor** Christian KROPF Art Unit 1614 Michelle Graffeo **Examiner Name** 

**Filing Date** 

**Application Number** 

(use as many sheets as necessary) Sheet of

H 3763 PCT/US Attorney Docket Number

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number – Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-5,514,210	5/7/96	Hirota et al.		
		US-5,320,844	6/14/94	Liu		
		US-4,853,225	8/1/89	Wahlig et al.		
		US-4,191,747	3/4/80	Scheicher		
		US-4,322,398	3/30/82	Reiner et al.		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Country	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵	
		Country Code <sup>3</sup> -Number <sup>4</sup> – Kind Code <sup>2</sup> (if known)					
		JP 10-017449	1/20/98	Japan		Х	
		EP 0 786 245 B1	6/12/02	Europe			
		WO 00/03747	1/27/00	PCT			
		DE 195 02 167	8/1/96	Germany		X	
		DE 1 165 574	3/19/64	Germany (GB962,919)			
		GB 962,919	7/8/64	Great Britain			
		WO 99/20237	4/29/99	PCT			
		WO 01/01930 A2	1/11/01	PCT (CA 2 373 955)			
		CA 2 373 955	1/11/01	Canada			

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1				
		Sakuma et al., Compositions for Treatment of Hypersenstive Tooth Pain, Chemical Abstracts, Accession No. XP-002156976, JP10017449			
		G. Willman, Mat-wiss. U. Werkstofftech, Wiley-VCH Verlag GmbH , Implants Coated with Hydroxyapit:The Option for Joining Metal to Hard Tissue, 30, pgs. 317-325, (1999)	Х		
		Flautre et al., Journal of Materials Science:Materials in Mecidine, Evaluation of Hydroxyapatite Powder Coated with Collagen as an Injectable Bone Substitute:Microscopic Study in Rabbit, 7, pgs. 63-67 (1996)			
		Wang et al., Journal of Materials Science Letters, Synthesis of nanophase hydroxapatite/collagen composite, 14, pgs. 490-492 (1995)			
		Schuster et al., Cosmetics & Toiletries, Protein Chemistry as Related to Cosmetics and Toiletries, 99, pgs. 63-74 (1984)			
		"Polyelectrolyte", AccessScience@McGraw-Hill, http://acessscience.com, l@ 200-2004 McGraw Hill Companies			
		Kirk-Othmer Encyclopedia of Chemical Technology Copyright© 1993 by John Wiley & Sons, Inc. DOP: 10.1002/0471238961.0405142016010405.a001; Article Online Posting Date: December 4, 2000			
		S. Zhang and K.E. Gonsalves, J. Mater. Sci. Maetwe, Med. 8 (1997) 25			

Examiner	Da	te	
Signature	Co	nsidered	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Yind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English Language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, US. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.